News

Filter

Current filters:

XalkoriResearch

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

25-03-2014

US pharma behemoth Pfizer says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK)…

OncologyPfizerPharmaceuticalResearchXalkori

ESMO 2012 Congress highlights

01-10-2012

The European Society for Medical Oncology (ESMO) Congress kicked off in Vienna, Austria, last Friday…

GlaxoSmithKlineJanssenJohnson & JohnsonOncologyPazopanib TabletsPfizerPharmaceuticalResearchXalkoriZytiga

Pfizer and Roche hope to score with ESMO presentations, notes GlobalData

25-09-2012

The European Society for Medical Oncology (ESMO) will kick off its 2012 annual meeting on Friday, September…

BiotechnologyHerceptinOncologyPfizerPharmaceuticalResearchRocheXalkori

75% of US oncologists prescribe Pfizer's Xalkori just 10 months after the drug's launch

21-06-2012

US oncologists surveyed by advisory firm Decision Resources say they prescribe drugs behemoth Pfizer's…

GlaxoSmithKlineHerceptinMarkets & MarketingNorth AmericaOncologyPfizerPharmaceuticalResearchRocheTarcevaTykerbXalkori

Back to top